Right now, cancer immunotherapy is entering a new stage.
With the advent of a new immunotherapy called neoantigen, treatment options for patients are expanding significantly, and the combination of conventional standard treatment and immunotherapy is also important.
The evolution of genetic analysis technology and immunotherapy for cancer, including neoantigen, has given rise to new hopes and expectations for cancer treatment.